Immune-inflammatory mechanisms in IFNγ-mediated anti-tumor activity

Seminars in Cancer Biology

Volumn 10, Issue 2, 2000, Pages 113-123

  Tannenbaum, Charles S ^a   Hamilton, Thomas A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; TUMOR VACCINE;

ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; LEUKOCYTE ACTIVATION; NONHUMAN; REVIEW; TUMOR; TUMOR MODEL;

EID: 0033909434     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2000.0314     Document Type: Article

References (146)

1. Wheelock E F. Interferon like virus inhibitor induced in human leukocytes by phytohemagglutinin. Science. 149:1965;310-311.
2. Pestka S, Langer J A, Zoon K C, Samuel C E. Interferons and their actions. Annu Rev Biochem. 56:1987;727-777.
3. Stewart W E. The Interferons. 1979;Springer Verlag, New York.
4. Henco K, Brosius J, Fujisawa A, Fujisawa J I, Haynes J R, Hochstadt J, Kovacic T, Pasek M, Schambock A, Schmid J et al. Structural relationship of human interferon alpha genes and pseudogenes. J Mol Biol. 185:1985;227-260.
5. Farrar M A, Screiber R D. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 11:1993;571-611.
6. Bancroft G J, Schreiber R D, Unanue E R. T cell-independent macrophage activation in scid mice. Curr Top Microbiol Immunol. 152:1989;235-242.
7. Bancroft G J, Schreiber R D, Unanue E R. Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. Immunol Rev. 124:1991;5-24.
8. Vilcek J, Gray P W, Rinderknect E, Sevastopoulos C G. Interferon gamma: a lymphokine for all seasons. Lymphokines. 11:1985;1-32.
9. Mosmann T R, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 17:1996;138-146.
10. Mosmann T R, Li L, Hengartner H, Kagi D, Fu W, Sad S. Differentiation and functions of T cell subsets. Ciba Found Symp. 204:1997;148.
11. Kupfer A, Mosmann T R, Kupfer H. Polarized expression of cytokines in cell conjugates of helper T cells and splenic B cells. Proc Natl Acad Sci USA. 88:1991;775-779.
12. Street N E, Mosmann T R. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 5:1991;171-177.
13. Schultz R M, Altom M G. Protective activity of recombinant murine tumor necrosis factor-alpha and interferon-gamma against experimental murine lung carcinoma metastases. J Interferon Res. 10:1990;229-236.
14. Brunda M J, Sulich v, Bellantoni D. The anti-tumor effect of recombinant interferon alpha or gamma is influenced by tumor location. Int J Cancer. 40:1987;807-810.
15. Hillman G G, Younes E, Visscher D, Hamzavi F, Kim S, Lam J S, Montecillo E J, Ali E, Pontes J E, Puri R K, Haas G P. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4. Clin Cancer Res. 3:1997;1799-1806.
16. Sunkara P S, Bowlin T L, Rosenberger A L, Fleischman W R, Jr. Effect of murine alpha-, beta-, and gamma-interferons in combination with alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on the tumor growth and metastasis of B16 melanoma and Lewis lung carcinoma in mice. J Biol Response Mod. 8:1989;170-179.
17. Koren S, Fleischmann W R, Jr. Quantitation of in vivo potentiation resulting from combined interferon therapy: antitumor effect against B-16 melanoma in mice. J Interferon Res. 6:1986;473-482.
18. van Moorselaar R J, Hendriks B T, van Stratum P, Van der Meide P H, Debruyne F M, Schalken J A. Synergistic antitumor effects of rat gamma-interferon and human tumor necrosis factor alpha against androgen-dependent and -independent rat prostatic tumors. Cancer Res. 51:1991;2329-2334.
19. Brouckaert P G, Leroux-Roels G G, Guisez Y, Tavernier J, Fiers W. In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer. 38:1986;763-769.
20. Weiner L M. Applications of gamma-interferon in cancer therapy. Mol Biother. 3:1991;186-191.
21. Agarwala S S, Kirkwood J M. Interferons in melanoma. Curr Opin Oncol. 8:1996;167-174.
22. Cavallo F, Di Pierro F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Forni M, Modesti A, Forni G. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 53:1993;5067-5070.
23. Forni G, Giovarelli M, Cavallo F, Consalvo M, Allione A, Modesti A, Musiani P, Colombo M P. Cytokine-induced tumor immunogenicity: From exogenous cytokines to gene therapy. J Immunother. 14:1993;253-257.
24. Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo M P, Lollini P L, Forni G. Cytokines, tumour-cell death and immunogenicity: A question of choice. Immunol Today. 18:1997;32-36.
25. Pardoll D M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol. 13:1995;399-415.
26. Colombo M P, Forni G. Immunotherapy. I: cytokine gene transfer strategies. Cancer Metastasis Rev. 16:1997;421-432.
27. Colombo M P, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today. 15:1994;48-51.
28. Watanabe Y. Transfection of interferon-gamma gene in animal tumors-a model for local cytokine production and tumor immunity. Semin Cancer Biol. 3:1992;43-46.
29. Gilboa E, Lyerly H K, Vieweg J, Saito S. Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol. 5:1994;409-417.
30. Sadanaga N, Nagoshi M, Lederer J A, Joo H G, Eberlein T J, Goedegebuure P S. Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells. Immunother. 22:1999;315-323.
31. Yoon S J, Heo D S, Kang J O, Lee S G, Kim C D, Sung M W, Kim N K. Synergistic anti-tumor effects with co-expression of GM-CSF and IFN-gamma in murine tumors. Int J Cancer. 77:1998;907-912.
32. Yanagihara K, Seyama T, Watanabe Y. Antitumor potential of interferon-gamma: retroviral expression of mouse interferon-gamma cDNA in two kinds of highly metastatic mouse tumor lines reduces their tumorigenicity. Nat Immun. 13:1994;102-112.
33. Musiani P, Allione A, Modica A, Lollini P L, Giovarelli M, Cavallo F, Belardelli F, Forni G, Modesti A. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-a, IFN-gamma, and TNF-a. Lab Invest. 74:1996;146-157.
34. Fathallah-Shaykh H M, Zhao L J, Kafrouni A I, Smith G M, Forman J. Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J Immunol. 164:2000;217-222.
35. Brunda M J, Luistro L, Warrier R R, Wright R B, Hubbard B R, Murphy M, Wolf S F, Gately M K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 178:1993;1223-1230.
36. Brunda M J, Gately M K. Antitumor activity of interleukin-12. Clin Immunol Immunopathol. 71:1994;253-255.
37. Brunda M J, Luistro L, Rumennik L, Wright R B, Dvorozniak M, Aglione A, Wigginton J M, Wiltrout R H, Hendrzak J A, Palleroni A V. Antitumor activity of inerleukin 12 in preclinical models. Cancer Chemother Pharmacol. 38 Suppl:1996;S16-S21.
38. Nastala C L, Edington H D, McKinney T G, Tahara H, Nalesnik M A, Brunda M J, Gately M K, Wolf S F, Schreiber R D, Storkus W J, Lotze M T. Recombinant interleukin-12 (IL-12) administration induces tumor regression in association with interferon-gamma production. J Immunol. 153:1994;1697-1706.
39. Zitvogel L, Tahara H, Robbins P D, Storkus W J, Clarke M R, Nalesnik M A, Lotze M T. Cancer immunotherapy of established tumors with IL-12: Effective delivery by genetically engineered fibroblasts. J Immunol. 155:1995;1393-1403.
40. Tahara H, Lotze M, Robbins P D, Storkus W J, Zitvogel L. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther. 6:1995;1607-1624.
41. Gautam S C, Chikkala N F, Ganapathi R, Hamilton T A. Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma. Cancer Res. 22:1991;6133-6137.
42. Tahara H, Zitvogel L, Storkus W J, Zeh H J, III, McKinney T G, Schreiber R D, Gubler U, Robbins P D, Lotze M T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol. 154:1995;6466-6474.
43. Brunda M J, Luistro L, Hendrzak J A, Fountoulakis M, Garotta G, Gately M K. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother. 17:1995;71-77.
44. Voest E E, Kenyon B M, O'Reilly M S, Truitt G, D'Amato R J, Folkman J. Inhibition of angiogenesis in vivo by Interleukin 12. JNCI. 87:1995;581-586.
45. Tannenbaum C S, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski R M, Hamilton T A. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol. 156:1996;693-699.
46. Tannenbaum C S, Tubbs R, Armstrong D, Finke J H, Bukowski R M, Hamilton T A. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol (in press). 1998.
47. Rubin B Y, Vaithilingam S, Martimucci W A. Comparative antiproliferative efficacies of human alpha and gamma interferons. J Gen Virol. 64:1983;1743-1748.
48. Levy-Strumpf N, Kimchi A. Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions. Oncogene. 17:1998;3331-3340.
49. Kimchi A. DAP genes: novel apoptotic genes isolated by a functional approach to gene cloning. Biochim Biophys Acta. 1377:1998;F13-F33.
50. Chin Y E, Kitagawa M, Kuida K, Flavell R A, Fu X Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol. 17:1997;5328-5337.
51. Mumberg D, Monach P A, Wanderling S, Philip M, Toledano A Y, Schreiber R D, Schreiber H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA. 96:1999;8633-8638.
52. Sonouchi K, Hamilton T A, Tannenbaum C S, Tubbs R R, Bukowski R, Finke J H. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2. Am J Pathol. 4:1994;747-755.
53. Dighe A S, Richards E, Old L J, Schreiber R D. Enhanced in vivo growth and resisitance to rejection of tumor cells expressing dominant negative IFNγ receptors. Immunity. 1:1994;447-456.
54. Dighe A S, Farrar M A, Schreiber R D. Inhibition of cellular responsiveness to interferon-gamma (IFNgamma) induced by overexpression of inactive forms of the IFNgamma receptor. J Biol Chem. 268:1993;10645-10653.
55. Kaplan D H, Shankaran V, Dighe A S, Stockert E, Aguet M, Old L J, Schreiber R D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 95:1998;7556-7561.
56. Erhlich P. Ned Tijdcshr Geneeskd. 5:1909;273-290.
57. Stutman O. Chemical carcinogenesis in nude mice: comparison between nude mice from homozgous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst. 62:1979;353-358.
58. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science. 183:1974;534-536.
59. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, Vilcek J, Zinkernagel R M, Aguet M. Immune response in mice that lack the interferon-gamma receptor. Science. 259:1993;1742-1745.
60. Meraz M A, White J M, Sheenhan K CF, Dighe A S, La[;am D H, Riley J K, Greenlund A C, Campbell D, Carver- Moore K, Dubois R N, Clark R, Aguet M, Schreiber R D. Targeted disruption of the STAT1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 84:1996;431-442.
61. Ralph S J, Wines B D, Payne M J, Grubb D, Hatzinisiriou I, Linnane A W, Devenish R J. Resistance of melanoma cell lines to interferons correlates with reduction of IFN-induced tyrosine phosphorylation. Induction of the anti-viral state by IFN is prevented by tyrosine kinase inhibitors. J Immunol. 154:1995;2248-2256.
62. Lee K Y, Anderson E, Madani K, Rosen G D. Loss of STAT1 expression confers resistance to IFN-gamma-induced apoptosis in ME180 cells. FEBS Lett. 459:1999;323-326.
63. Chatterjee-Kishore M, Kishore R, Hicklin D J, Marincola F M, Ferrone S. Different requirements for signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J Biol Chem. 273:1998;16177-16183.
64. Wong L H, Krauer K G, Hatzinisiriou I, Estcourt M J, Hersey P, Tam N D, Edmondson S, Devenish R J, Ralph S J. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem. 272:1997;28779-28785.
65. Bach E A, Aguet M, Schreiber R D. The IFNgamma receptor: A paradigm for cytokine receptor signaling. Annu Rev Immunol. 15:1997;563-591.
66. Stark G R, Kerr I M, Williams B R, Silverman R H, Schreiber R D. How cells respond to interferons. Annu Rev Biochem. 67:1998;227-264.
67. Der S D, Zhou A, Williams B R, Silverman R H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA. 95:1998;15623-15628.
68. Durbin J E, Hackenmiller R, Simon M C, Levy D E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 84:1996;443-450.
69. Ramana C V, Grammatikakis N, Chernov M, Nguyen H, Goh K C, Williams B RG, Stark G R. Regulation of c-myc xpression by IFN γ through STAT1-dependent and STAT1-independent pathways. EMBO J. 19:2000;263-272.
70. Adams D O, Hamilton T A. The cell biology of macrophage activation. [review]. Annu Rev Immunol. 2:1984;283-318.
71. Adams D O, Hamilton T A. Molecular basis of macrophage activation: diversity and its origins. Lewis C E, O'D McGee J. The Natural Immune System. 1992;75-114 Oxford University Press, Oxford/New York.
72. Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol. 11:1999;76-81.
73. Boehm U, Klamp T, Groot M, Howard J C. Cellular responses to interferon-gamma. Annu Rev Immunol. 15:1997;749-795.
74. Kapsenberg M L, Hilkens C M, Wierenga E A, Kalinski P. The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy. Clin Exp Allergy. 29 Suppl 2:1999;33-36.
75. Goerdt S, Orfanos C E. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity. 10:1999;137-142.
76. Mantovani A. Biology of disease. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Invest. 71:1994;5-16.
77. 2. J Immunol. 153:1994;1674-1686.
78. Elgert K D, Alleva D G, Mullins D W. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol. 64:1998;275-290.
79. Pabst R, Westermann J. Which steps in lymphocyte recirculation are regulated by interferon-gamma? Res Immunol. 145:1994;289-294.
80. Tsokos G C. Lymphocytes, cytokines, inflammation, and immune trafficking. Curr Opin Rheumatol. 8:1996;395-402.
81. Adams D O, Hamilton T A. Macrophages as destructive cells in host defense. Gallin J I, Goldstein I M, Snyderman R. Inflammation: Basic Principles and Clinical Correlates. 1992;637-662 Raven Press, New York.
82. Monaco J J. Pathways for the processing and presentation of antigens to T cells. J Leukoc Biol. 57:1995;543-547.
83. Uebel S, Tampe R. Specificity of the proteasome and the TAP transporter. Curr Opin Immunol. 11:1999;203-208.
84. Nandi D, Marusina K, Monaco J J. How do endogenous proteins become peptides and reach the endoplasmic reticulum. Curr Top Microbiol Immunol. 232:1998;15-47.
85. van Endert P M. Genes regulating MHC class I processing of antigen. Curr Opin Immunol. 11:1999;82-88.
86. Wingren A G, Parra E, Varga M, Kalland T, Sjogren H O, Hedlund G, Dohlsten M. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol. 15:1995;235-253.
87. Piskurich J F, Linhoff M W, Wang Y, Ting J P. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol Cell Biol. 19:1999;431-440.
88. -/-mice. Immunity. 5:1996;365-376.
89. Wright K L, White L C, Kelly A, Beck S, Trowsdale J, Ting J P. Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J Exp Med. 181:1995;1459-1471.
90. Ohmori Y, Schreiber R D, Hamilton T A. Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem. 272:1997;14899-14907.
91. Johnson D R, Pober J S. HLA class I heavy-chain gene promoter elements mediating synergy between tumor necrosis factor and interferons. Mol Cell Biol. 14:1994;1322-1332.
92. Steimle V, Siegrist C-A, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon g mediated by transactivator gene CIITA. Science. 265:1994;106-109.
93. Steimle V, Durand B, Barras E, Zufferey M, Hadam M R, Mach B, Reith W. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9:1995;1021-1032.
94. Ting J P, Baldwin A S. Regulation of MHC gene expression. Curr Opin Immunol. 5:1993;8-16.
95. Wright R L, Chin K C, Linhoff M, Skinner C, Brown J A, Boss J M, Stark G R, Ting J P. CIITA stimulation of transcription factor binding to major histocompatibility complex class II and associated promotersin vivo. Proc Natl Acad Sci USA. 95:1998;6267-6272.
96. Gobin S J, Peijnenburg A, van Eggermond M, van Zutphen M, van den Berg R, Van den Elsen P J. The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes. Immunity. 9:1998;531-541.
97. Johnsen A K, Templeton D J, Sy M, Harding C V. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol. 163:1999;4224-4231.
98. Johnsen A, France J, Sy M S, Harding C V. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res. 58:1998;3660-3667.
99. Singal D P, Ye M, Qiu X. Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines. Int J Cancer. 68:1996;629-636.
100. Signal D P, Ye M, Ni J, Snider D P. Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines. Immunol Lett. 50:1996;149-154.
101. Cromme F V, van Bommel P F, Walboomers J M, Gallee M P, Stern P L, Kenemans P, Helmerhorst T J, Stukark M J, Meijer C J. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer. 69:1994;1176-1181.
102. Springer T A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. [review]. Cell. 76:1994;301-314.
103. Springer T A. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol. 57:1995;827-872.
104. Butcher E C, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol. 72:1999;209-253.
105. Alexandroff A B, McIntyre C A, Porter J C, Zeuthen J, Vile R G, Taub D D. Sticky and smelly issues: lessons on tumour cell and leucocyte trafficking, gene and immunotherapy of cancer. Br J Cancer. 77:1998;1806-1811.
106. Brown N J, Ali S, Reed M W, Wiltrout R, Rees R C. Trafficking of activated lymphocytes into the RENCA tumour microcirculation in vivo in mice. Br J Cancer. 76:1997;1572-1578.
107. Dean P A, Ramsey P S, Donohue J H, Nelson H. Microvascular expression of MALA-2 correlates with in vivo lymphocyte trafficking and is preferentially enhanced in tumors by tumor necrosis factor-alpha and interleukin-1 alpha. Int J Cancer. 59:1994;639-645.
108. Luster A D. Review articles: mechanisms of disease: chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med. 338:1998;436-445.
109. Ben-Baruch A, Michiel D F, Oppenheim J J. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem. 270:1995;11703-11706.
110. Baggiolini M. Chemokines and leukocyte traffic. Nature. 392:1998;565-568.
111. Hamilton T A, Tannenbaum C S, Finke J H, Bukowski R M. Interactions between chemokines and other cytokines in host response to tumor. Rollins B J. Chemokines. 1999;115-126 Humana Press, Totawa.
112. Luster A D, Leder P. IP-10, A C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med. 178:1993;1057-1065.
113. Loetscher M, Gerber B, Loetscher P, Jones S A, Piali L, Clark-Lewis I, Baggiolini M, Moser B. Chemokine receptor specific for IP10 and Mig: structure, function and expression in activated T lymphocytes. J Exp Med. 184:1996;963-969.
114. Piali L, Weber C, LaRosa G, Mackay C R, Springer T A, Clark-Lewis I, Moser B. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol. 28:1998;961-972.
115. Angiolillo A L, Sgadari C, Taub D D, Liao F, Farber J M, Maheshwari S, Kleinman H K, Reaman G H, Tosato G. Human interferon inducible protein IP-10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 182:1995;155-162.
116. Sgadari C, Farber J M, Angiolillo A L, Liao F, Teruya-Feldstein J, Burd P R, Yao L, Gupta G, Kanegane C, Tosato G. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood. 89:1997;2635-2643.
117. Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Farber J M, Liao F, Liu L, Tosato G. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. Leukoc Biol. 64:1998;384-392.
118. Strieter R M, Polverini P J, Kunkel S L, Arenberg D A, Burdick M D, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 270:1995;27348-27357.
119. Keane M P, Arenberg D A, Lynch J P, III, Whyte R I, Iannettoni M D, Burdick M D, Wilke C A, Morris S B, Glass M C, DiGiovine B, Kunkel S L, Strieter R M. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol. 159:1997;1437-1443.
120. Arenberg D A, Polverini P J, Kunkel S L, Shanafelt A, Hesselgesser J, Horuk R, Strieter R M. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol. 62:1997;554-562.
121. Luster A D, Greenberg S M, Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med. 182:1995;219-231.
122. Arenberg D A, Kunkel S L, Polverini P J, Morris S B, Burdick M D, Glass M C, Taub D T, Iannettoni M D, Whyte T I, Strieter R M. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med. 184:1996;981-992.
123. Sgadari C, Angiolillo A L, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 87:1996;3877-3882.
124. Teruya-Feldstein J, Jaffe E S, Burd P R, Kanegane H, Kingma D W, Wilson W H, Longo D L, Tosato G. The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood. 90:1997;4099-4105.
125. Oliveira I C, Sciavolino P J, Lee J H, Vilcek J. Downregulation of interleukin 8 gene expression in human fibroblasts: Unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci USA. 89:1992;9049-9053.
126. Ohmori Y, Hamilton T A. IFN γ selectively inhibits lipopolysaccharide-inducible JE/monocyte chemoattractant protein-1 and KC/gro/melanoma growth-stimulating activity gene expression in mouse peritoneal macrophages. J Immunol. 5:1994;2204-2212.
127. Schnyder-Candrian S, Strieter R M, Kunkel S L, Walz A. Interferon-a and interferon-gamma down-regulate the production of interleukin-8 and ENA-78 in human monocytes. J Leukocyte Biol. 57:1995;929-935.
128. Kopydlowski K M, Salkowski C A, Cody M J, Van Rooijen N, Major J, Hamilton T A, Vogel S N. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol. 163:1999;1537-1544.
129. Strieter R M, Polverini P J, Arenberg D A, Kunkel S L. The role of CXC chemokines as regulators of angiogenesis. Shock. 4:1995;155-160.
130. Hamilton T A, Ohmori Y, Narumi S, Tannenbaum C S. Regulation of diversity in macrophage activation. Lopez-Berestein G, Klostergaard J. Mononuclear Phagocytes in Cell Biology. 1992;47-70 CRC Press, New York.
131. Nathan C F, Cohn Z A. Cellular components of inflammation: monocytes and macrophages. Kelly W, Harris E, Ruddy S, Hedge R. Textbook of Rheumatology. 1995;144-169 WB Saunders, New York.
132. MacMicking J, Xie Q W, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 15:1997;323-350.
133. Nathan C, Xie Q W. Nitric oxide synthases: roles, tolls, and controls. Cell. 78:1994;915-918.
134. Weinberg J B. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med. 4:1998;557-591.
135. Wang Y, Marsden P A. Nitric oxide synthases: gene structure and regulation. Adv Pharmacol. 34:1995;71-90.
136. Forstermann U, Kleinert H, Gath I, Schwarz P, Closs E I, Dun N J. Expression and expressional control of nitric oxide synthases in various cell types. Adv Pharmacol. 34:1995;171-186.
137. Xie K, Fidler I J. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev. 17:1998;55-75.
138. Thomsen L L, Miles D W. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev. 17:1998;107-118.
139. Xie K, Dong Z, Fidler I J. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol. 59:1996;797-803.
140. Tozer G M, Everett S A. Nitric oxide in tumor biology and cancer therapy. Part 2: Therapeutic implications. Clin Oncol (R Coll Radiol). 9:1997;357-364.
141. Jenkins D C, Charles I G, Thomsen L L, Moss D W, Holmes L S, Baylis S A, Rhodes P, Westmore K, Emson P C, Moncada S. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA. 92:1995;4392-4396.
142. Yim C Y, McGregor J R, Kwon O D, Bastian N R, Rees M, Mori M, Hibbs J B, Jr, Samlowski W E. Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor. J Immunol. 155:1995;4382-4390.
143. Ezekowitz R A, Orkin S H, Newburger P E. Recombinant interferon gamma augments phagocyte superoxide production and x-chronic granulomatous disease gene expression in x-linked variant chronic granulomatous disease. J Clin Invest. 80:1987;1009-1016.
144. Bastian N R, Hibbs J B, Jr. Assembly and regulation of NADPH oxidase and nitric oxide synthase. Curr Opin Immunol. 6:1994;131-139.
145. Burke F, Knowles R G, East N, Balkwill F R. The role of indoleamine 2,3-dioxygenase in the anti-tumor activity of human interferon-gamma in vivo. Int J Cancer. 60:1995;115-122.
146. Hissong B D, Carlin J M. Potentiation of interferon-induced indoleamine 2,3-dioxygenase mRNA in human mononuclear phagocytes by lipopolysaccharide and interleukin-1. J Interferon Cytokine Res. 17:1997;387-393.